Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: September 20, 2012
Last updated: August 9, 2016
Last verified: August 2016
This multicenter, randomized, double-blind, placebo-controlled study will assess the efficacy, safety and tolerability of aleglitazar monotherapy compared with placebo in patients with type 2 diabetes mellitus who have not previously received anti-hyperglycemic therapy. Patients will be randomized to receive oral doses of 150 mcg aleglitazar once daily or placebo. The anticipated time on study treatment is 26 weeks.

Condition Intervention Phase
Diabetes Mellitus Type 2
Drug: Placebo
Drug: aleglitazar
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess the Efficacy, Safety and Tolerability of Aleglitazar Monotherapy Compared With Placebo in Patients With Type 2 Diabetes Mellitus (T2D) Who Are Drug-Naïve to Anti-Hyperglycemic Therapy

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Change from baseline in hemoglobin HbA1c [ Time Frame: From baseline to week 26 ]

Secondary Outcome Measures:
  • Change in lipid profile [ Time Frame: From baseline to week 26 ]
  • Change from baseline in fasting plasma glucose [ Time Frame: From baseline to week 26 ]
  • Responder rate as defined of hemoglobin A1c (HbAc1) <7.0% (<6.5%) [ Time Frame: From baseline to week 26 ]
  • Change from baseline in homeostatic index of insulin sensitivity (HOMA-IS) [ Time Frame: From baseline to week 26 ]
  • Change from baseline in homeostatic index of beta cell function (HOMA-BCF) [ Time Frame: From baseline to week 26 ]
  • Safety: incidence of adverse events [ Time Frame: 30 weeks (26 weeks treatment and 4 weeks follow-up) ]

Enrollment: 196
Study Start Date: November 2012
Study Completion Date: September 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: Placebo
oral doses once a day for 26 weeks
Experimental: aleglitazar Drug: aleglitazar
150 mcg orally once a day for 26 weeks


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult patients, >/=18 years of age
  • Diagnosis of diabetes mellitus, type 2 within 12 months prior to screening
  • Patients who have not received a anti-hyperglycemic medication for at least 12 weeks prior to screening and for not longer than 3 consecutive months in the past
  • HbA1c >/=7% and </=9.5% at screening or within 4 weeks prior to screening and at pre-randomization visit
  • Fasting plasma glucose </=240 mg/dL at pre-randomization visit
  • Agreement to maintain diet and exercise habits during the study

Exclusion Criteria:

  • Patients with Type 1 diabetes mellitus, secondary diabetes, diabetes resulting from pancreatic injury, or acute metabolic diabetic complications within the past 6 months
  • Any previous treatment with thiazolidinedione or a dual peroxisome proliferator activated receptor (PPAR) agonist
  • Any body weight lowering or lipoprotein-modifying therapy within 12 weeks prior to screening (except stable dose of statin)
  • Symptomatic congestive heart failure classified as New York Heart Association class II-IV at screening
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01691755

  Hide Study Locations
United States, California
Chino, California, United States, 91710
Los Angeles, California, United States, 90057
Santa Ana, California, United States, 92701
Thousand Oaks, California, United States, 91360
Upland, California, United States, 91786
West Hills, California, United States, 91307
United States, Florida
Boynton Beach, Florida, United States, 33472
Cooper City, Florida, United States, 33024
Coral Gables, Florida, United States, 33134
Jacksonville, Florida, United States, 32216
Kissimmee, Florida, United States, 34741
United States, Georgia
Atlanta, Georgia, United States, 30338
United States, Illinois
Chicago, Illinois, United States, 60607
United States, Indiana
Avon, Indiana, United States, 46123
United States, Missouri
St Peters, Missouri, United States, 63376
United States, North Carolina
Greensboro, North Carolina, United States, 27408
United States, Oregon
Portland, Oregon, United States, 97239
United States, Pennsylvania
Altoona, Pennsylvania, United States, 16602
Scranton, Pennsylvania, United States, 18510
Tipton, Pennsylvania, United States, 16684
United States, South Carolina
Greer, South Carolina, United States, 29651
United States, Tennessee
Knoxville, Tennessee, United States, 37919
United States, Washington
Spokane, Washington, United States, 99202
Aguascaliente, Mexico, 20230
Cuernavaca, Mexico, 62250
Culiacan, Mexico, 80020
Durango, Mexico, 34000
Durango, Mexico, 34080
Guadalajara, Mexico, 44600
Mexico City, Mexico, 11650
Monterrey, Mexico, 64460
Pachuca, Mexico, 42090
Queretaro, Mexico, 76000
Tampico, Mexico, 89000
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Hoffmann-La Roche Identifier: NCT01691755     History of Changes
Other Study ID Numbers: BC28034
Study First Received: September 20, 2012
Last Updated: August 9, 2016

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on April 21, 2017